Multiple sourcing Framework Contracts to speed up the development of and access to innovative medical countermeasures - Next Generation Therapeutics for Infectious Diseases (HADEA/2026/OP/0015-PIN)
A new HERA funding action is soon to be launched in close collaboration with the Health and Digital Executive Agency (HaDEA). This call for tenders aims to speed up the development of promising next-generation therapeutics for infectious diseases by adopting a competitive development in phases under Pre-Commercial Procurement (PCP).
The scope of the call is expected to cover the development of innovative therapeutics to treat viral infections, as well as acute respiratory distress syndrome (ARDS) or sepsis resulting from infections. This includes both pathogen-targeted therapeutics (excluding small molecules and monoclonal antibodies) and host-targeted approaches, including but not limited to direct-acting antivirals, indirect-acting antivirals and novel immune modulators.
The call may also cover innovative combination therapies and products designed to be administered through alternative routes to intravenous delivery. Broad-spectrum therapeutics, pathogen-agnostic approaches, and solutions that could reduce or counteract the emergence of viral resistance are of particular interest.
- Indicative type of procedure: Open call for tenders
- Indicative type of contract: Framework Contract with reopen of competition
- Indicative duration: 108 month
- Indicative FWC budget: EUR 244 000 000
- Estimated date of publication of a contract notice: 27/05/2026
We encourage you to subscribe to all call for tenders and share this information with all potentially interested entities within your networks. You are also invited to use the portal’s dedicated pages to post any questions you might have.
Finally, we invite you to update yourself on this, or any subsequent calls, by checking regularly HaDEA’s website and LinkedIn, HERA’s website, and the EU in Emergencies LinkedIn.